Company intelligence / Profile preview
Curon Biopharmaceutical
Shanghai, Chinacuronbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Curon's lead asset CN201, a next-generation CD3xCD19 bispecific antibody designed to deplete B cells by engaging T cells, has shown promising early clinical data. It demonstrated activity in patients with relapsed or refractory B-cell hematologic malignancies such as non-Hodgkin’s lymphoma and acute lymphocytic leukemia. The therapy was well tolerated with low rates of cytokine release syndrome and no neurotoxicity observed in safety datasets. This led to Merck acquiring global rights to CN201 for $700 million upfront plus up to $600 million in milestones[2][6][8][10].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesBispecific T-cell engagers (BiTE)Antibody-drug conjugates (ADC)Cytokines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Merck – acquisition of investigational drug CN201[2][6]Rhizen Pharmaceuticals – exclusive licensing agreement for Tenalisib in Greater China[7]
Beyond the preview
Go deeper on Curon Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curon Biopharmaceutical.